Financial Difficulty in Patients With Blood Cancer

Completed

Conditions studied: Chronic Lymphocytic Leukemia, Multiple Myeloma

In brief

This is a hypothesis-driven, observational, cross-sectional, multi-site study of the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250) (Appendix A), a physician survey (n=100) (Appendix B), and a practice survey completed by each site enrolling patients onto this study (Appendix C). A subset of enrolled patients (n=35) will be invited to participate in an optional second telephone interview (Appendix D). This study will measure the prevalence of patient-reported financial difficulty, specific financial burdens and resources currently available to patients and from practices to assist with patient financial navigation.

Key facts

Study ID

NCT05212233

Run by

UNC Lineberger Comprehensive Cancer Center

People needed

218

Starts

2022-01-27

Expected to finish

2025-02-26

Last updated by the study team

2025-09-26

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PATIENT ELIGIBILITY CRITERIA
• Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)
• Patients' medical records must be available to the registering institution
• Eligible patients must have been prescribed drug-based anticancer therapy, whether administered orally or by infusion, within the prior 12 months. Specifically, eligible patients are those who:
• Are presently being treated with infused or orally-administered anticancer therapy, OR
• Completed infused or orally-administered anti-cancer therapy in the past 12 months, OR
• Were prescribed infused or orally-administered anticancer therapy within the prior 12 months yet chose to forego treatment
• Not currently enrolled in a clinical trial in which drug is supplied by the study
• Patients with psychiatric illness or other mental impairment that would preclude their ability to give informed consent or to respond to the telephone survey are not eligible
• Patients must be able to read and comprehend English or Spanish
• SITE ELIGIBILITY CRITERIA
• Intent to complete the Practice Survey
• Access to patient medical records: Registering institution must have access to patient medical records, either on site or via request from other institutions, if recruiting patients at a site (as medical abstraction is required for collecting study data).
• Sites seeking to enroll Spanish- speaking patients must have Spanish speaking staff on site or through the use of a translation service to be able to conduct the informed consent discussion in Spanish.
• PHYSICIAN ELIGIBILITY CRTERIA
• The physician currently treats patients with chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM).
• The physician is a treating physician at a site which has opened this protocol (LCCC 2063) and/or a site which opened the Alliance protocol (A231602CD; ClinicalTrials.gov Identifier: NCT03870633). Eligible physicians do not need to have their own patients enrolled onto this protocol.

Where it is running

• University Of Alabama At Birmingham — Birmingham, Alabama, United States
• Mayo Clinic Cancer Center — Phoenix, Arizona, United States
• Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah, Georgia, United States
• LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana, United States
• Albert Einstein College of Medicine — The Bronx, New York, United States
• UNC Medical Center — Chapel Hill, North Carolina, United States
• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.